At a December 8 hearing, the House Committee on Energy and Commerce’s Subcommittee on Health explored recent price hikes by pharmaceutical manufacturers that appear to anticipate pending health system reform legislation that could affect drug costs.
Stephen W. Schondelmeyer, PhD, PharmD, of the University of Minnesota in Minneapolis, testified that he estimated that brand-name prescription drug prices increased an average of 9.3% in the 12-month period that culminated at the end of September 2009, while general inflation decreased by only 0.3%.
Mitka M. Price Hikes Probed. JAMA. 2010;303(2):125. doi:10.1001/jama.2009.1954